- Home
- TNGX vs PHAT Comparison
TNGX vs PHAT Comparison
Compare TNGX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- PHAT
- Stock Information
- Founded
- TNGX 2014
- PHAT 2018
- Country
- TNGX United States
- PHAT United States
- Employees
- TNGX N/A
- PHAT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- PHAT Health Care
- Exchange
- TNGX Nasdaq
- PHAT Nasdaq
- Market Cap
- TNGX 723.2M
- PHAT 820.8M
- IPO Year
- TNGX N/A
- PHAT 2019
- Fundamental
- Price
- TNGX $6.63
- PHAT $11.62
- Analyst Decision
- TNGX Strong Buy
- PHAT Strong Buy
- Analyst Count
- TNGX 6
- PHAT 5
- Target Price
- TNGX $10.00
- PHAT $16.40
- AVG Volume (30 Days)
- TNGX 1.3M
- PHAT 1.1M
- Earning Date
- TNGX 11-05-2025
- PHAT 11-06-2025
- Dividend Yield
- TNGX N/A
- PHAT N/A
- EPS Growth
- TNGX N/A
- PHAT N/A
- EPS
- TNGX N/A
- PHAT N/A
- Revenue
- TNGX $24,296,000.00
- PHAT $114,039,000.00
- Revenue This Year
- TNGX $6.56
- PHAT $207.52
- Revenue Next Year
- TNGX N/A
- PHAT $96.46
- P/E Ratio
- TNGX N/A
- PHAT N/A
- Revenue Growth
- TNGX N/A
- PHAT 1049.82
- 52 Week Low
- TNGX $1.03
- PHAT $2.21
- 52 Week High
- TNGX $10.85
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- TNGX 49.24
- PHAT 53.72
- Support Level
- TNGX $6.25
- PHAT $11.89
- Resistance Level
- TNGX $7.40
- PHAT $13.00
- Average True Range (ATR)
- TNGX 0.40
- PHAT 0.72
- MACD
- TNGX -0.05
- PHAT -0.11
- Stochastic Oscillator
- TNGX 33.04
- PHAT 21.14
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.